Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1927 3
1929 1
1940 1
1952 1
1954 1
1955 2
1957 1
1961 3
1962 1
1963 1
1964 1
1965 7
1966 6
1968 7
1969 3
1970 7
1971 8
1972 10
1973 3
1974 5
1975 2
1976 5
1977 6
1978 7
1979 8
1980 10
1981 6
1982 7
1983 2
1984 6
1985 12
1986 8
1987 10
1988 7
1989 13
1990 14
1991 22
1992 21
1993 19
1994 24
1995 25
1996 21
1997 30
1998 32
1999 27
2000 16
2001 18
2002 24
2003 17
2004 20
2005 13
2006 17
2007 13
2008 15
2009 22
2010 13
2011 22
2012 24
2013 20
2014 29
2015 29
2016 25
2017 22
2018 27
2019 38
2020 31
2021 56
2022 41
2023 43
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

951 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, Otani S, Shimizu J, Katakami N, Azuma K, Miura N, Nishino K, Hara S, Teraoka S, Morita S, Nakagawa K, Yamamoto N. Akamatsu H, et al. Among authors: otani s. JAMA Oncol. 2021 Mar 1;7(3):386-394. doi: 10.1001/jamaoncol.2020.6758. JAMA Oncol. 2021. PMID: 33410885 Free PMC article. Clinical Trial.
p53 Deficiency-Dependent Oncogenicity of Runx3.
Ito K, Otani S, Date Y. Ito K, et al. Among authors: otani s. Cells. 2023 Apr 10;12(8):1122. doi: 10.3390/cells12081122. Cells. 2023. PMID: 37190031 Free PMC article. Review.
Critical illness and the role of the microbiome.
Otani S, Chihade DB, Coopersmith CM. Otani S, et al. Acute Med Surg. 2018 Dec 27;6(2):91-94. doi: 10.1002/ams2.383. eCollection 2019 Apr. Acute Med Surg. 2018. PMID: 30976432 Free PMC article. Review.
Gut integrity in critical illness.
Otani S, Coopersmith CM. Otani S, et al. J Intensive Care. 2019 Mar 20;7:17. doi: 10.1186/s40560-019-0372-6. eCollection 2019. J Intensive Care. 2019. PMID: 30923621 Free PMC article. Review.
FI: The Fecobiome Initiative.
Sapountzis P, Teseo S, Otani S, Aarestrup FM, Forano E, Suen G, Tsiamis G, Haley B, Van Kessel JA, Huws SA. Sapountzis P, et al. Among authors: otani s. Foodborne Pathog Dis. 2022 Jul;19(7):441-447. doi: 10.1089/fpd.2021.0082. Epub 2021 Dec 21. Foodborne Pathog Dis. 2022. PMID: 34936494 Free PMC article.
Extrapulmonary hamartoma.
Endo T, Endo S, Hasegawa T, Tetsuka K, Yamamoto S, Otani S, Kanai Y, Tezuka Y. Endo T, et al. Among authors: otani s. Gen Thorac Cardiovasc Surg. 2011 Mar;59(3):209-11. doi: 10.1007/s11748-010-0634-7. Epub 2011 Mar 30. Gen Thorac Cardiovasc Surg. 2011. PMID: 21448803
Surgical outcome of ipsilateral anatomical resection for lung cancer after pulmonary lobectomy.
Okazaki M, Suzawa K, Shien K, Yamamoto H, Araki K, Watanabe M, Okada M, Maki Y, Ueno T, Otani S, Sugimoto R, Nishikawa H, Okita R, Hayama M, Tao H, Fujiwara T, Inokawa H, Hirami Y, Sano Y, Yamashita M, Kawamata O, Matsuura M, Toyooka S. Okazaki M, et al. Among authors: otani s. Eur J Cardiothorac Surg. 2023 Mar 1;63(3):ezad048. doi: 10.1093/ejcts/ezad048. Eur J Cardiothorac Surg. 2023. PMID: 36752515 Free PMC article.
951 results